Evidence map›Paper›PMID 34996939›Full record

ArticleScientific reports2022

Validation of a combined ultrasound and bioluminescence imaging system with magnetic resonance imaging in orthotopic pancreatic murine tumors.

Juan D Rojas, Jordan B Joiner, Brian Velasco, Kathlyne Jayne B Bautista, Adam M Aji, Christopher J Moore, Nathan J Beaumont, Yuliya Pylayeva-Gupta, Paul A Dayton, Ryan C Gessner and 1 more

Open access · goldAbstract readComparative StudyValidation Study
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.0field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Juan D RojasSonoVol, Inc, Durham, NC, USA.
Jordan B JoinerDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA.
Brian VelascoJoint Department of Biomedical Engineering, University of North Carolina and North Carolina State University, Chapel Hill, NC, USA.
Kathlyne Jayne B BautistaJoint Department of Biomedical Engineering, University of North Carolina and North Carolina State University, Chapel Hill, NC, USA.
Adam M AjiSonoVol, Inc, Durham, NC, USA.
Christopher J MooreSonoVol, Inc, Durham, NC, USA.
Nathan J BeaumontSonoVol, Inc, Durham, NC, USA.
Yuliya Pylayeva-GuptaLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Paul A DaytonJoint Department of Biomedical Engineering, University of North Carolina and North Carolina State University, Chapel Hill, NC, USA.
Ryan C GessnerSonoVol, Inc, Durham, NC, USA.
Tomasz J CzernuszewiczSonoVol, Inc, Durham, NC, USA. tomekc@sonovol.com.
SonoVol (United States) · USNorth Carolina State University · USUniversity of North Carolina at Chapel Hill · US

Funding

Development of a mobile and automated platform for multiplexed multi-modality imagingR44CA192482 · NCI · SONOVOL, INC. · PI GESSNER, RYAN · 2017 to 2019
$2.2M
Parametric optimization of ultrasound-mediated immuno-modulation for pancreatic cancer therapyR21CA246550 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAYTON, PAUL A, PYLAYEVA-GUPTA, YULIYA · 2020 to 2022
$392k
A turnkey research platform to accelerate clinical translation of focused-ultrasound (FUS) oncology therapiesR43CA239830 · NCI · SONOVOL, INC. · PI GESSNER, RYAN · 2019 to 2019
$300k
National Science Foundation DGE-1650116NCI NIH HHS R21 CA246550NCI NIH HHS R43 CA239830NCI NIH HHS R44 CA192482NIH HHS R44CA192482
6 · The paper itself

Abstract

Preclinical mouse solid tumor models are widely used to evaluate efficacy of novel cancer therapeutics. Recent reports have highlighted the need for utilizing orthotopic implantation to represent clinical disease more accurately, however the deep tissue location of these tumors makes longitudinal assessment challenging without the use of imaging techniques. The purpose of this study was to evaluate the performance of a new multi-modality high-throughput in vivo imaging system that combines bioluminescence imaging (BLI) with robotic, hands-free ultrasound (US) for evaluating orthotopic mouse models. Long utilized in cancer research as independent modalities, we hypothesized that the combination of BLI and US would offer complementary advantages of detection sensitivity and quantification accuracy, while mitigating individual technological weaknesses. Bioluminescent pancreatic tumor cells were injected into the pancreas tail of C57BL/6 mice and imaged weekly with the combination system and magnetic resonance imaging (MRI) to serve as a gold standard. BLI photon flux was quantified to assess tumor activity and distribution, and US and MRI datasets were manually segmented for gross tumor volume. Robotic US and MRI demonstrated a strong agreement (R

Indexed as

Magnetic Resonance ImagingOptical ImagingUltrasonographyAnimalsCell Line, TumorDisease ProgressionEarly Detection of CancerHigh-Throughput Screening AssaysMiceMice, Inbred C57BLMultimodal ImagingPancreatic NeoplasmsPredictive Value of TestsReproducibility of ResultsTime FactorsTumor Burden

Identifiers

PMID34996939
PMCPMC8741958
OpenAlexW4205879152

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.